Gilead Sciences (GILD) Q1 'As Good as it Gets' - Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Gilead Sciences (GILD) Q1 Results Called 'Outstanding' at Wells Fargo
April 23, 2014 9:36 AM EDTWells Fargo maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $87-$91. Analyst Brian Abrahams described Q1 results as "outstanding."
"On 4/22, GILD reported outstanding quarterly results, with Sovaldi sales likely exceeding most sell/buyside expectations, some... More
Gilead (GILD) Q1 'One of Most Impressive Beats in Biopharma History' - Piper Jaffray
April 23, 2014 8:51 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Gilead Sciences (NASDAQ: GILD) and bumped his price target price target from $105 to $106 following impressive Q1 results and said the stock is officially a 'value' stock.
Schimmer comments, "GILD reported one of the... More
Goldman Sachs Comments on Gilead Sciences (GILD) Q1
April 23, 2014 7:46 AM EDTGoldman Sachs maintained a Neutral rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $65.00 (from $63.00).
Analyst Terence Flynn said, "Sovaldi posted an impressive beat in its first full quarter on the US market... More
Gilead Sciences, Inc. (GILD) Tops Q1 EPS by 61c, Offers Guidance
April 22, 2014 4:30 PM EDTGilead Sciences, Inc. (NASDAQ: GILD) reported Q1 EPS of $1.46, $0.61 better than the analyst estimate of $0.85. Revenue for the quarter came in at $5 billion versus the consensus estimate of $3.8 billion.
Full Year 2014 Guidance
Gilead reiterates its full year 2014 guidance, initially provided on February 4, 2014,... More
